MedTrace Logo

IL-2 PET Imaging in Advanced Solid Tumours

NCT05471271 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-05-31

No results posted yet for this study

Summary

This is an investigator-initiated, single-center, open-label clinical trial designed to evaluate the safety and PK of the PET tracer \[18F\]AlF-RESCA-IL2 in patients prior to and during treatment.

Conditions

  • Metastatic Solid Tumor

Interventions

OTHER

[18F]AlF-RESCA-IL2 PET scan

Patients will undergo \[18F\]AlF-RESCA-IL2 PET imaging twice; the first \[18F\]AlF-RESCA-IL2 PET scan will be performed at baseline, before starting therapy. The second \[18F\]AlF-RESCA-IL2 PET scan will be performed after 2 weeks of treatment

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-02
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05471271 on ClinicalTrials.gov